^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure

                   Table 1 of trt by CRIT4FL
                   Controlling for SSNRISN=1

            trt
                           CRIT4FL(Criterion 4 Evaluation 
                                   Result Flag)

            Frequency     ‚
            Percent       ‚
            Row Pct       ‚
            Col Pct       ‚N       ‚Y       ‚  Total
            ƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
            JZP150 0.3 mg ‚      1 ‚      0 ‚      1
                          ‚  50.00 ‚   0.00 ‚  50.00
                          ‚ 100.00 ‚   0.00 ‚
                          ‚  50.00 ‚      . ‚
            ƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
            Total                2        0        2
                            100.00     0.00   100.00
            (Continued)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure

                   Table 1 of trt by CRIT4FL
                   Controlling for SSNRISN=1

            trt
                           CRIT4FL(Criterion 4 Evaluation 
                                   Result Flag)

            Frequency     ‚
            Percent       ‚
            Row Pct       ‚
            Col Pct       ‚N       ‚Y       ‚  Total
            ƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
            Placebo       ‚      1 ‚      0 ‚      1
                          ‚  50.00 ‚   0.00 ‚  50.00
                          ‚ 100.00 ‚   0.00 ‚
                          ‚  50.00 ‚      . ‚
            ƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
            Total                2        0        2
                            100.00     0.00   100.00
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure

                   Table 2 of trt by CRIT4FL
                   Controlling for SSNRISN=2

            trt
                           CRIT4FL(Criterion 4 Evaluation 
                                   Result Flag)

            Frequency     ‚
            Percent       ‚
            Row Pct       ‚
            Col Pct       ‚N       ‚Y       ‚  Total
            ƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
            JZP150 0.3 mg ‚      6 ‚      0 ‚      6
                          ‚  42.86 ‚   0.00 ‚  42.86
                          ‚ 100.00 ‚   0.00 ‚
                          ‚  50.00 ‚   0.00 ‚
            ƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
            Total               12        2       14
                             85.71    14.29   100.00
            (Continued)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure

                   Table 2 of trt by CRIT4FL
                   Controlling for SSNRISN=2

            trt
                           CRIT4FL(Criterion 4 Evaluation 
                                   Result Flag)

            Frequency     ‚
            Percent       ‚
            Row Pct       ‚
            Col Pct       ‚N       ‚Y       ‚  Total
            ƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
            Placebo       ‚      6 ‚      2 ‚      8
                          ‚  42.86 ‚  14.29 ‚  57.14
                          ‚  75.00 ‚  25.00 ‚
                          ‚  50.00 ‚ 100.00 ‚
            ƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
            Total               12        2       14
                             85.71    14.29   100.00
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure

             Summary Statistics for trt by CRIT4FL
                    Controlling for SSNRISN

  Cochran-Mantel-Haenszel Statistics (Based on Table Scores)
 
Statistic    Alternative Hypothesis    DF       Value      Prob
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
    1        Nonzero Correlation        1      1.6250    0.2024
    2        Row Mean Scores Differ     1      1.6250    0.2024
    3        General Association        1      1.6250    0.2024
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Summary Statistics for trt by CRIT4FL
                    Controlling for SSNRISN

             Common Odds Ratio and Relative Risks
 
   Statistic                   Method                  Value
   ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
   Odds Ratio                  Mantel-Haenszel              
                               Logit **               5.0000

   Relative Risk (Column 1)    Mantel-Haenszel        1.2791
                               Logit                  1.3333

   Relative Risk (Column 2)    Mantel-Haenszel        0.0000
                               Logit **               0.2571

             Common Odds Ratio and Relative Risks
 
   Statistic                   Method  95% Confidence Limits
   ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
   Odds Ratio                  Mantel-Haenszel              
                               Logit **               0.1988
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Summary Statistics for trt by CRIT4FL
                    Controlling for SSNRISN

             Common Odds Ratio and Relative Risks
 
   Statistic                   Method  95% Confidence Limits
   ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
   Relative Risk (Column 1)    Mantel-Haenszel        0.9086
                               Logit                  0.8937

   Relative Risk (Column 2)    Mantel-Haenszel              
                               Logit **               0.0146

             Common Odds Ratio and Relative Risks
 
   Statistic                   Method  95% Confidence Limits
   ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
   Odds Ratio                  Mantel-Haenszel              
                               Logit **             125.7847

   Relative Risk (Column 1)    Mantel-Haenszel        1.8006
                               Logit                  1.9893
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Summary Statistics for trt by CRIT4FL
                    Controlling for SSNRISN

             Common Odds Ratio and Relative Risks
 
   Statistic                   Method  95% Confidence Limits
   ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
   Relative Risk (Column 2)    Mantel-Haenszel              
                               Logit **               4.5408

  To avoid undefined results, some estimates are not computed.
** These logit estimators use a correction of 0.5 in every cell 
                                
                                 
                                 
                                o
                               f 
                               th
                               os
                               e 
                               ta
                               bl
                               es
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Summary Statistics for trt by CRIT4FL
                    Controlling for SSNRISN

                                t
                               ha
                               t 
                               co
                               nt
                               ai
                               n 
                               a 
                               ze
                               ro
                               . 
                               Ta
                               bl
                               es
                                w
                               it
                               h 
                               a 
                               ze
                               ro
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Summary Statistics for trt by CRIT4FL
                    Controlling for SSNRISN

                                
                                 
                                 
                                r
                               ow
                                o
                               r 
                               a 
                               ze
                               ro
                                c
                               ol
                               um
                               n 
                               ar
                               e 
                               no
                               t 
                               in
                               cl
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Summary Statistics for trt by CRIT4FL
                    Controlling for SSNRISN

                               ud
                               ed
                                i
                               n 
                               co
                               mp
                               ut
                               in
                               g 
                               th
                               e 
                                 
                                 
                                l
                               og
                               it
                                e
                               st
                               im
                               at
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Summary Statistics for trt by CRIT4FL
                    Controlling for SSNRISN

                               or
                               s.


  Breslow-Day Statistic not computed--the data are too sparse.


                     Total Sample Size = 16
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure

                    Table of trt by CRIT4FL

            trt
                           CRIT4FL(Criterion 4 Evaluation 
                                   Result Flag)

            Frequency     ‚
            Percent       ‚
            Row Pct       ‚
            Col Pct       ‚N       ‚Y       ‚  Total
            ƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
            JZP150 0.3 mg ‚      7 ‚      0 ‚      7
                          ‚  43.75 ‚   0.00 ‚  43.75
                          ‚ 100.00 ‚   0.00 ‚
                          ‚  50.00 ‚   0.00 ‚
            ƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
            Total               14        2       16
                             87.50    12.50   100.00
            (Continued)
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure

                    Table of trt by CRIT4FL

            trt
                           CRIT4FL(Criterion 4 Evaluation 
                                   Result Flag)

            Frequency     ‚
            Percent       ‚
            Row Pct       ‚
            Col Pct       ‚N       ‚Y       ‚  Total
            ƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
            Placebo       ‚      7 ‚      2 ‚      9
                          ‚  43.75 ‚  12.50 ‚  56.25
                          ‚  77.78 ‚  22.22 ‚
                          ‚  50.00 ‚ 100.00 ‚
            ƒƒƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
            Total               14        2       16
                             87.50    12.50   100.00
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure

             Statistics for Table of trt by CRIT4FL

                    Column 1 Risk Estimates
 
                                          (Asymptotic) 95%
                      Risk        ASE     Confidence Limits
    ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
    Row 1           1.0000     0.0000     1.0000     1.0000
    Row 2           0.7778     0.1386     0.5062     1.0000
    Total           0.8750     0.0827     0.7130     1.0000

    Difference      0.2222     0.1386    -0.0494     0.4938

                 Difference is (Row 1 - Row 2)

                                  (Exact) 95%
                               Confidence Limits
               ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
               Row 1           0.5904     1.0000
               Row 2           0.3999     0.9719
               Total           0.6165     0.9845

                 Difference is (Row 1 - Row 2)
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Statistics for Table of trt by CRIT4FL

                                  (Exact) 95%
                               Confidence Limits
               ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
               Difference                       

                 Difference is (Row 1 - Row 2)


     Confidence Limits for the Proportion (Risk) Difference
                Proportion Difference = 0.2222
 
         Type                    95% Confidence Limits

         Newcombe (Corrected)    -0.2534        0.5981

                    Column 1 (CRIT4FL = N)
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Statistics for Table of trt by CRIT4FL

                    Column 2 Risk Estimates
 
                                          (Asymptotic) 95%
                      Risk        ASE     Confidence Limits
    ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
    Row 1           0.0000     0.0000     0.0000     0.0000
    Row 2           0.2222     0.1386     0.0000     0.4938
    Total           0.1250     0.0827     0.0000     0.2870

    Difference     -0.2222     0.1386    -0.4938     0.0494

                 Difference is (Row 1 - Row 2)

 
 
                                  (Exact) 95%
                               Confidence Limits
               ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
               Row 1           0.0000     0.4096

                 Difference is (Row 1 - Row 2)
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Statistics for Table of trt by CRIT4FL

 
 
                                  (Exact) 95%
                               Confidence Limits
               ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
               Row 2           0.0281     0.6001
               Total           0.0155     0.3835

               Difference                       

                 Difference is (Row 1 - Row 2)

                        Sample Size = 16
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure

                   Table 1 of trt by CRIT4FL
                   Controlling for SSNRISN=1

             trt
                          CRIT4FL(Criterion 4 Evaluation Result 
                                  Flag)

             Frequency   ‚
             Percent     ‚
             Row Pct     ‚
             Col Pct     ‚N       ‚Y       ‚  Total
             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
             JZP150 4 mg ‚      2 ‚      0 ‚      2
                         ‚  66.67 ‚   0.00 ‚  66.67
                         ‚ 100.00 ‚   0.00 ‚
                         ‚  66.67 ‚      . ‚
             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
             Total              3        0        3
                           100.00     0.00   100.00
             (Continued)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure

                   Table 1 of trt by CRIT4FL
                   Controlling for SSNRISN=1

             trt
                          CRIT4FL(Criterion 4 Evaluation Result 
                                  Flag)

             Frequency   ‚
             Percent     ‚
             Row Pct     ‚
             Col Pct     ‚N       ‚Y       ‚  Total
             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
             Placebo     ‚      1 ‚      0 ‚      1
                         ‚  33.33 ‚   0.00 ‚  33.33
                         ‚ 100.00 ‚   0.00 ‚
                         ‚  33.33 ‚      . ‚
             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
             Total              3        0        3
                           100.00     0.00   100.00
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure

                   Table 2 of trt by CRIT4FL
                   Controlling for SSNRISN=2

             trt
                          CRIT4FL(Criterion 4 Evaluation Result 
                                  Flag)

             Frequency   ‚
             Percent     ‚
             Row Pct     ‚
             Col Pct     ‚N       ‚Y       ‚  Total
             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
             JZP150 4 mg ‚      9 ‚      0 ‚      9
                         ‚  52.94 ‚   0.00 ‚  52.94
                         ‚ 100.00 ‚   0.00 ‚
                         ‚  60.00 ‚   0.00 ‚
             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
             Total             15        2       17
                            88.24    11.76   100.00
             (Continued)
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure

                   Table 2 of trt by CRIT4FL
                   Controlling for SSNRISN=2

             trt
                          CRIT4FL(Criterion 4 Evaluation Result 
                                  Flag)

             Frequency   ‚
             Percent     ‚
             Row Pct     ‚
             Col Pct     ‚N       ‚Y       ‚  Total
             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
             Placebo     ‚      6 ‚      2 ‚      8
                         ‚  35.29 ‚  11.76 ‚  47.06
                         ‚  75.00 ‚  25.00 ‚
                         ‚  40.00 ‚ 100.00 ‚
             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
             Total             15        2       17
                            88.24    11.76   100.00
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure

             Summary Statistics for trt by CRIT4FL
                    Controlling for SSNRISN

  Cochran-Mantel-Haenszel Statistics (Based on Table Scores)
 
Statistic    Alternative Hypothesis    DF       Value      Prob
ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
    1        Nonzero Correlation        1      2.4000    0.1213
    2        Row Mean Scores Differ     1      2.4000    0.1213
    3        General Association        1      2.4000    0.1213
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Summary Statistics for trt by CRIT4FL
                    Controlling for SSNRISN

             Common Odds Ratio and Relative Risks
 
   Statistic                   Method                  Value
   ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
   Odds Ratio                  Mantel-Haenszel              
                               Logit **               7.3077

   Relative Risk (Column 1)    Mantel-Haenszel        1.2755
                               Logit                  1.3333

   Relative Risk (Column 2)    Mantel-Haenszel        0.0000
                               Logit **               0.1800

             Common Odds Ratio and Relative Risks
 
   Statistic                   Method  95% Confidence Limits
   ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
   Odds Ratio                  Mantel-Haenszel              
                               Logit **               0.2991
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Summary Statistics for trt by CRIT4FL
                    Controlling for SSNRISN

             Common Odds Ratio and Relative Risks
 
   Statistic                   Method  95% Confidence Limits
   ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
   Relative Risk (Column 1)    Mantel-Haenszel        0.9096
                               Logit                  0.8937

   Relative Risk (Column 2)    Mantel-Haenszel              
                               Logit **               0.0099

             Common Odds Ratio and Relative Risks
 
   Statistic                   Method  95% Confidence Limits
   ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
   Odds Ratio                  Mantel-Haenszel              
                               Logit **             178.5729

   Relative Risk (Column 1)    Mantel-Haenszel        1.7886
                               Logit                  1.9893
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Summary Statistics for trt by CRIT4FL
                    Controlling for SSNRISN

             Common Odds Ratio and Relative Risks
 
   Statistic                   Method  95% Confidence Limits
   ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
   Relative Risk (Column 2)    Mantel-Haenszel              
                               Logit **               3.2705

  To avoid undefined results, some estimates are not computed.
** These logit estimators use a correction of 0.5 in every cell 
                                
                                 
                                 
                                o
                               f 
                               th
                               os
                               e 
                               ta
                               bl
                               es
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Summary Statistics for trt by CRIT4FL
                    Controlling for SSNRISN

                                t
                               ha
                               t 
                               co
                               nt
                               ai
                               n 
                               a 
                               ze
                               ro
                               . 
                               Ta
                               bl
                               es
                                w
                               it
                               h 
                               a 
                               ze
                               ro
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Summary Statistics for trt by CRIT4FL
                    Controlling for SSNRISN

                                
                                 
                                 
                                r
                               ow
                                o
                               r 
                               a 
                               ze
                               ro
                                c
                               ol
                               um
                               n 
                               ar
                               e 
                               no
                               t 
                               in
                               cl
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Summary Statistics for trt by CRIT4FL
                    Controlling for SSNRISN

                               ud
                               ed
                                i
                               n 
                               co
                               mp
                               ut
                               in
                               g 
                               th
                               e 
                                 
                                 
                                l
                               og
                               it
                                e
                               st
                               im
                               at
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Summary Statistics for trt by CRIT4FL
                    Controlling for SSNRISN

                               or
                               s.


  Breslow-Day Statistic not computed--the data are too sparse.


                     Total Sample Size = 20
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure

                    Table of trt by CRIT4FL

             trt
                          CRIT4FL(Criterion 4 Evaluation Result 
                                  Flag)

             Frequency   ‚
             Percent     ‚
             Row Pct     ‚
             Col Pct     ‚N       ‚Y       ‚  Total
             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
             JZP150 4 mg ‚     11 ‚      0 ‚     11
                         ‚  55.00 ‚   0.00 ‚  55.00
                         ‚ 100.00 ‚   0.00 ‚
                         ‚  61.11 ‚   0.00 ‚
             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
             Total             18        2       20
                            90.00    10.00   100.00
             (Continued)
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure

                    Table of trt by CRIT4FL

             trt
                          CRIT4FL(Criterion 4 Evaluation Result 
                                  Flag)

             Frequency   ‚
             Percent     ‚
             Row Pct     ‚
             Col Pct     ‚N       ‚Y       ‚  Total
             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
             Placebo     ‚      7 ‚      2 ‚      9
                         ‚  35.00 ‚  10.00 ‚  45.00
                         ‚  77.78 ‚  22.22 ‚
                         ‚  38.89 ‚ 100.00 ‚
             ƒƒƒƒƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆƒƒƒƒƒƒƒƒˆ
             Total             18        2       20
                            90.00    10.00   100.00
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure

             Statistics for Table of trt by CRIT4FL

                    Column 1 Risk Estimates
 
                                          (Asymptotic) 95%
                      Risk        ASE     Confidence Limits
    ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
    Row 1           1.0000     0.0000     1.0000     1.0000
    Row 2           0.7778     0.1386     0.5062     1.0000
    Total           0.9000     0.0671     0.7685     1.0000

    Difference      0.2222     0.1386    -0.0494     0.4938

                 Difference is (Row 1 - Row 2)

                                  (Exact) 95%
                               Confidence Limits
               ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
               Row 1           0.7151     1.0000
               Row 2           0.3999     0.9719
               Total           0.6830     0.9877

                 Difference is (Row 1 - Row 2)
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Statistics for Table of trt by CRIT4FL

                                  (Exact) 95%
                               Confidence Limits
               ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
               Difference                       

                 Difference is (Row 1 - Row 2)


     Confidence Limits for the Proportion (Risk) Difference
                Proportion Difference = 0.2222
 
         Type                    95% Confidence Limits

         Newcombe (Corrected)    -0.1475        0.5981

                    Column 1 (CRIT4FL = N)
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Statistics for Table of trt by CRIT4FL

                    Column 2 Risk Estimates
 
                                          (Asymptotic) 95%
                      Risk        ASE     Confidence Limits
    ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
    Row 1           0.0000     0.0000     0.0000     0.0000
    Row 2           0.2222     0.1386     0.0000     0.4938
    Total           0.1000     0.0671     0.0000     0.2315

    Difference     -0.2222     0.1386    -0.4938     0.0494

                 Difference is (Row 1 - Row 2)

 
 
                                  (Exact) 95%
                               Confidence Limits
               ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
               Row 1           0.0000     0.2849

                 Difference is (Row 1 - Row 2)
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.4.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Secondary Eff
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                       The FREQ Procedure
 
             Statistics for Table of trt by CRIT4FL

 
 
                                  (Exact) 95%
                               Confidence Limits
               ƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒƒ
               Row 2           0.0281     0.6001
               Total           0.0123     0.3170

               Difference                       

                 Difference is (Row 1 - Row 2)

                        Sample Size = 20
 
 
 
 
 
 
 
 
 
^S={}PGI-S: Patient Global Impression of Severity, CI: Confidenc
^S={}Note: The Modified Full Analysis Set includes all participa
^S={}Note: Continuity corrected Wilson’s 95% CI as modified by N
^S={}Note: Percentages are based on the total number of particip
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
